NCR101

NCR101 is an investigational cell therapy developed by Nuwacell Biotechnologies for the treatment of interstitial lung disease (ILD). It is currently being evaluated in a Phase 1/2 clinical trial to assess its safety, tolerability, and preliminary efficacy in patients with ILD. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) regimens. Interstitial lung disease encompasses a group of disorders characterized by inflammation and/or fibrosis of the alveolar units, leading to progressive loss of lung function. Existing treatments such as pirfenidone and nintedanib can slow disease progression but do not cure ILD or significantly improve survival, highlighting the need for novel therapies like NCR101[1][2][3][4]. While specific details about the mechanism of action or cell type are not disclosed in public sources, it is likely that NCR101 involves a regenerative or immunomodulatory approach typical for advanced cell therapies.

Other names

NCR-101NCR101NCR 101